Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine-MedSci.cn

Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine

McGinley, JS; L'Italien, GJ; Thiry, A; Croop, R; Coric, V; Lipton, RB

NEUROLOGY, 2020; 94 (15):

科室
- - 订阅+
  - 更多科室
工具
服务